Literature DB >> 29567802

Mycoplasma genitalium: high prevalence of resistance to macrolides and frequent anorectal infection in men who have sex with men in western Sydney.

Deborah L Couldwell1,2, Dean Jalocon3, Melissa Power1, Neisha J Jeoffreys3, Sharon C-A Chen2,3, David A Lewis1,2.   

Abstract

OBJECTIVES: We aimed to estimate the prevalence of Mycoplasma genitalium infection and of mutations linked to macrolide resistance using the ResistancePlus MG assay (SpeeDx, Sydney, New South Wales, Australia) in first-void urine (FVU), anorectal and oropharyngeal samples from men who have sex with men (MSM) attending Western Sydney Sexual Health Centre (WSSHC).
METHODS: Consecutive symptomatic and asymptomatic MSM attending for STI testing were prospectively enrolled. M. genitalium testing using the ResistancePlus MG assay was performed on FVU, anorectal and oropharyngeal samples routinely collected for Chlamydia trachomatis and Neisseria gonorrhoeae assays.
RESULTS: Overall, the prevalence of M. genitalium infection in the study group was 13.4% (68/508). Most (79.4%, 54/68) M. genitalium harboured macrolide resistance mutations (87.5% of urethral and 75.6% of anorectal infections). The anorectum was the most commonly infected site (45/505, 8.9%), followed by the urethra (24/508, 4.7%). No oropharyngeal M. genitalium infections were detected (0/508). Most of the anorectal (93.3%) and urethral (79.2%) infections were asymptomatic.MSM who were taking HIV pre-exposure prophylaxis (PrEP) were twice as likely to be infected with M. genitalium compared with MSM who were not on PrEP (OR 2.1, 95% CI 1.3 to 3.6; P=0.0041). Always using condoms for anal sex in the last 3 months was protective of infection (OR 0.8, 95% CI 0.6 to 1.0; P=0.0186).
CONCLUSIONS: We demonstrated a high prevalence of M. genitalium and very high levels of macrolide resistance among MSM attending WSSHC. Our findings support the routine use of an assay to detect macrolide resistance mutations in M. genitalium infections. This will ensure, in regions or populations with high rates of macrolide resistance among M. genitalium strains, that first-line treatment with azithromycin will only be used if a macrolide-sensitive strain is identified. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  anorectal; azithromycin; drug resistance; men who have sex with men; mycoplasma genitalium; prevalence

Mesh:

Substances:

Year:  2018        PMID: 29567802     DOI: 10.1136/sextrans-2017-053480

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  19 in total

Review 1.  Mycoplasma genitalium and Trichomonas vaginalis: addressing disparities and promoting public health control of two emerging sexually transmitted infections.

Authors:  Faye Korich; Neha G Reddy; Maria Trent
Journal:  Curr Opin Pediatr       Date:  2020-08       Impact factor: 2.856

2.  Genotyping of Mycoplasma genitalium Suggests De Novo Acquisition of Antimicrobial Resistance in Queensland, Australia.

Authors:  Emma L Sweeney; Jacob Tickner; Cheryl Bletchly; Graeme R Nimmo; David M Whiley
Journal:  J Clin Microbiol       Date:  2020-08-24       Impact factor: 5.948

3.  Prevalence of Mycoplasma genitalium and Antibiotic Resistance-Associated Mutations in Patients at a Sexually Transmitted Infection Clinic in Iceland, and Comparison of the S-DiaMGTV and Aptima Mycoplasma genitalium Assays for Diagnosis.

Authors:  Ingibjörg Hilmarsdóttir; Eva Mjöll Arnardóttir; Elísabet Reykdal Jóhannesdóttir; Freyja Valsdóttir; Daniel Golparian; Ronza Hadad; Hannes Bjarki Vigfússon; Magnus Unemo
Journal:  J Clin Microbiol       Date:  2020-08-24       Impact factor: 5.948

4.  Lack of Association Between the S83I ParC Mutation in Mycoplasma genitalium and Treatment Outcomes Among Men Who Have Sex With Men with Nongonococcal Urethritis.

Authors:  Laura C Chambers; Jørgen S Jensen; Jennifer L Morgan; M Sylvan Lowens; Sarah S Romano; Patricia A Totten; Olusegun O Soge; James P Hughes; Matthew R Golden; Lisa E Manhart
Journal:  Sex Transm Dis       Date:  2019-12       Impact factor: 2.830

Review 5.  Mycoplasma genitalium: A new superbug.

Authors:  J Stephen Raj; Jyoti Rawre; Neha Dhawan; Neena Khanna; Benu Dhawan
Journal:  Indian J Sex Transm Dis AIDS       Date:  2022-06-07

6.  Incidence of sexually transmitted infections in men who have sex with men and who are at substantial risk of HIV infection - A meta-analysis of data from trials and observational studies of HIV pre-exposure prophylaxis.

Authors:  Ricardo Niklas Werner; Matthew Gaskins; Alexander Nast; Corinna Dressler
Journal:  PLoS One       Date:  2018-12-03       Impact factor: 3.240

7.  Macrolide-Resistant Mycoplasma genitalium in Southeastern Region of the Netherlands, 2014-2017.

Authors:  Liesbeth Martens; Sharon Kuster; Wilco de Vos; Maikel Kersten; Hanneke Berkhout; Ferry Hagen
Journal:  Emerg Infect Dis       Date:  2019-07       Impact factor: 6.883

8.  Symptoms, Sites, and Significance of Mycoplasma genitalium in Men Who Have Sex with Men.

Authors:  Tim R H Read; Gerald L Murray; Jennifer A Danielewski; Christopher K Fairley; Michelle Doyle; Karen Worthington; Jenny Su; Elisa Mokany; L T Tan; David Lee; Lenka A Vodstrcil; Eric P F Chow; Suzanne M Garland; Marcus Y Chen; Catriona S Bradshaw
Journal:  Emerg Infect Dis       Date:  2019-04       Impact factor: 6.883

9.  High prevalence of circulating dual-class resistant Mycoplasma genitalium in asymptomatic MSM in Tokyo, Japan.

Authors:  Naokatsu Ando; Daisuke Mizushima; Misao Takano; Morika Mitobe; Hirofumi Miyake; Keiko Yokoyama; Kenji Sadamasu; Takahiro Aoki; Koji Watanabe; Haruka Uemura; Yasuaki Yanagawa; Hiroyuki Gatanaga; Shinichi Oka
Journal:  JAC Antimicrob Resist       Date:  2021-06-30

10.  MgpB Types among Mycoplasma genitalium Strains from Men Who Have Sex with Men in Berlin, Germany, 2016-2018.

Authors:  Roger Dumke; Marcos Rust; Tobias Glaunsinger
Journal:  Pathogens       Date:  2019-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.